PRESENTATION

FY2021 — Results presentation

FY2021PDF · 81 pages13.9 MB
AUDITED RESULTS
FOR THE YEAR ENDED 30 JUNE 2021

-- 1 of 81 --

2
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health	
Vitality Health	
Vitality Car	
Vitality Life	
Vitality Invest
Global Network
USA
+9% core new business API, i.e. excluding DH
take-on of new closed schemes and gross
revenue for Vitality Group
New business
+11%
to R22 595m
Normalised
operating profit
+7%
to R6 494m
Normalised
headline earnings
-9%
to R3 406m
Headline
earnings
+12%
to R3 711m
Life COVID-19
provisions
R2.8bn
NHE before forex
impact
+909%
to R2 986m

-- 2 of 81 --

3
The period under review
Resilient performance with operating profit up 7%, new
business up 11% and actuarial dynamics in line with
expectation
Navigating the significant impact of COVID-19; meeting our
core purpose and serving society by ensuring quick and
efficient vaccination of all South Africans
A pivot to growth by capitalising on the applicability of the
Vitality Shared-value model to ensure:
a) Organic growth
b) Geographic growth
c) Platform-led growth
1 Navigating
COVID-19
2 Resilient
operating
performance
3 Capital strength
and liquidity
4 Three
dimensions
of growth
Capital strength and liquidity remained a key focus - all
metrics above target and with sufficient buffers
Require capital for Ping An Health to support business
growth and product diversification

-- 3 of 81 --

Navigating COVID-19 and
meeting our core purpose
1

-- 4 of 81 --

5
Our strategic response to the pandemic
Maintain financial strength and resilience
Support
our country
Protect
our people
Protect and support our
clients
Employee vaccine
mandate
Structural and pricing
changes to products
Central role in state-led
COVID-19 response
Implement mandatory vaccination
policy from 1 January 2022
DSY offices and sites become
vaccination-only zones
Preferred premiums for vaccinated DL
members
Product incentives to vaccinate
R2 800m Life provisions across the Group
R2 448m DL earnings impact for period under review
9 DH vaccination sites
1 000 staff deployed
>550 000 vaccinations administered
- c5% of total national vaccinations
cR200m allocated to campaign
(R42m in this period)

-- 5 of 81 --

6
COVID-19 in South Africa was worse than predicted
Deaths (90% excess deaths)
DSY predicted the
first wave well
87k Discovery
medium
48k ASSA
Scenario 1
50k Government
model
12k PANDA
76k Actual deaths
(90% Excess
deaths)
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
Orig. Beta Delta
Infectious variant coincided with
holiday season
CFR for Beta variant higher
Delay in vaccination
programme
Higher proportion of
infections in younger
age groups
Initial predicted deaths to
Dec 20, at May 2020
DSY underestimated the peak of Wave 2 and the timing and extent of Wave 3
90% excess
deaths
DSY
prediction for
current FY

-- 6 of 81 --

7
SA’s epidemic was 5x worse than the UK’s
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
-
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
20200503	
20200517	
20200531	
20200614	
20200628	
20200712	
20200726	
20200809	
20200823	
20200906	
20200920	
20201004	
20201018	
20201101	
20201115	
20201129	
20201213	
20201227	
20210110	
20210124	
20210207	
20210221	
20210307	
20210321	
20210404	
20210418	
20210502	
20210516	
20210530	
20210613	
20210627	
20210711	
20210725	
20210808
Infections Deaths
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
-
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
20200503	
20200517	
20200531	
20200614	
20200628	
20200712	
20200726	
20200809	
20200823	
20200906	
20200920	
20201004	
20201018	
20201101	
20201115	
20201129	
20201213	
20201227	
20210110	
20210124	
20210207	
20210221	
20210307	
20210321	
20210404	
20210418	
20210502	
20210516	
20210530	
20210613	
20210627	
20210711	
20210725	
20210808
Infections Deaths
New cases
Deaths (90% excess)
New cases
Deaths
IFR Deaths
(90% excess)
Implied
infections Population % population
infected
0.39% -
0.5% 215k 45m 60m 70% - 80%
IFR Deaths
(90% excess)
Implied
infections Population % population
infected
1.09% 132k 12m 68m 18%
Given SA’s younger age profile, expect deaths to be 64% lower, but when adjusting for population size
(12% smaller) the data indicates epidemic currently 5.5x worse than UK
Vaccinations
decouple
infections
and deaths

-- 7 of 81 --

8
Factors that influence COVID-19 waves
COVID Wave = (1-Immunity) P(contact)	x Risk index	x
Population
immunity
Reinfection
rates
Vaccines
70%-80%
of the population
infected
20%-25%
of the population
re-infected
24%
of the population
vaccinated
Behaviour
COVID-19
variants
Community
prevalence
Resilience index
New variants
Risk of (re)infection At least 40% of the population are still vulnerable to new or reinfection	1
Reduced vulnerability Vaccinated and previously infected people have far higher levels of protection	2
3
Vaccination	4
Mobility
Social distancing
Mask wearing Life COVID-19 mortality rate by
Vitality status
>90%
effective in
reducing death
https://sacoronavirus.co.za/latest-vaccine-statistics/
Unknown
Changing
New variants are emerging constantly, e.g. C1.2. Awaiting data but probably lower
risk than Delta
Significant additional protection against severe disease and death

-- 8 of 81 --

9
Data supports efficacy of vaccination against COVID-19
1 Surveillance of influenza and other respiratory viruses in the UK Winter 2019 to 2020
2 Sisonke and SAMRC, test negative refreshed to 17 July
3 Test negative study refreshed to 15 August
COVID-19 vaccination reduces
risk of mortality relative to
influenza1
Deaths per million of the population
208
Without a
COVID vaccine
Influenza With a COVID
vaccine
8-10x
impact of flu 28%
reduction if
vaccinated
Confirmed
infection
Discovery Health data on vaccine effectiveness*
Vaccine is >90% effective in reducing death
Admission High care/ICU Death
J & J 28+ days since vaccination2
Pfizer 7+ days - second dose3
*Excludes data on members vaccinated in the public sector. To be submitted for peer review and publication
1 813
150
0
10
20
30
40
50
60
70
80
90
100
J & J Pfizer
0
10
20
30
40
50
60
70
80
90
100
J & J Pfizer
0
10
20
30
40
50
60
70
80
90
100
J & J Pfizer
0
10
20
30
40
50
60
70
80
90
100
J & J Pfizer
Reduction in
risk relative to
unvaccinated
50-80% Reduction in
risk relative to
unvaccinated
70-85% Reduction in
risk relative to
unvaccinated
70-90% Reduction in
risk relative to
unvaccinated
>90%

-- 9 of 81 --

10
0
2
4
6
8
10
12
14
16
18
5-Jul
19 Jul
2 Aug
16 Aug	
30 Aug	
13 Sep	
27 Sep	
11 Oct	
25 Oct	
08 Nov	
22 Nov	
06 Dec
Millions
J&J Pfizer
0.0
0.5
1.0
1.5
2.0
2.5
5-Jul
19-Jul
2-Aug
16-Aug
30-Aug
13-Sep
27-Sep
11-Oct
25-Oct
8-Nov
Millions
J&J Pfizer first Pfizer second
Demand generation is paramount to ensure capacity utilisation
Vaccination Profile (doses) Slow take up in
younger cohorts
First dose ramp up per age group
Discovery clients
vaccinated* by age band
Stock Profile
Delivery schedule
Daily doses based
on a 6 day week
Underutilised
capacity
xx
Millions
Supply Demand
Constraints
168
154
231
212
185	
204	
350
 -
370	
140	
250	
355	
325	
320	
315
275
0%
10%
20%
30%
40%
50%
60%
70%
80%
10-May
24-May
7-Jun
21-Jun
5-Jul
19-Jul
2-Aug
16-Aug
60+ 50-59
35-49 18-34
9 weeks
6 weeks
4 weeks
5 weeks
55%
40%
22%
4%
4 weeks
7 weeks
Millions
0%
10%
20%
30%
40%
50%
60%
70%
80%
10-May	
24-May
7-Jun
21-Jun
5-Jul
19-Jul
2-Aug
16-Aug
30-Aug
76%
65%
54%
25%
>101k Outbound calls
>19m Emails and SMSes sent
*partial or fully

-- 10 of 81 --

11
-
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2,000
20200201	
20200219	
20200308	
20200326	
20200413	
20200501	
20200519	
20200606	
20200624	
20200712	
20200730	
20200817	
20200904	
20200922	
20201010	
20201028	
20201115	
20201203	
20201221	
20210108	
20210126	
20210213	
20210303	
20210321	
20210408	
20210426	
20210514	
20210601	
20210619	
20210707	
20210725	
20210812	
20210830	
20210917	
20211005	
20211023	
20211110	
20211128	
20211216	
20220103	
20220121	
20220208	
20220226	
20220316	
20220403	
20220421	
20220509	
20220527	
20220614	
20220702	
20220720	
20220807	
20220825	
20220912	
20220930	
20221018	
20221105	
20221123	
20221211	
20221229
4th wave depends on the R factor and proportion of people
infected. Given the high infection rate, together with vaccines,
higher 4th wave mortality would require very high assumed R1
The likelihood of a mortality impact in the 4th wave is low
National incremental deaths scenarios
At least partially
vaccinated Fully
vaccinated
over age 60	Total
lives
Members
over age 60
Health 51.2% 76.2% 64.4%
Individual
Life2 61.8% 76.6% 62.1%
Group Life2 51.1% 78.4% 62.8%
Encouraging Discovery population
to get vaccinated
1 R assumption peaks at 1.5 in Medium, 1.6 in High and 2.0 in New variants
2 Sum assured weighted
90% excess
deaths Low Medium High No
Vaccine
Total (k) 235 240 245 265
Aiming to vaccinate
>80% 60+yrs members by end September
>80% whole book by end 2021
100% take-up of the 2nd dose where applicable
Actual % vaccinated
FY22	FY21	FY20

-- 11 of 81 --

12
Unprecedented health tragedy; with the fourth
wave posing further risk
COVID-19 vaccines are effective and safe
Public health imperative
Issue is no longer one of limited access to
vaccines, but one of hesitancy
Supported by a legal obligation to protect and safeguard all employees from all potential risks
1
2
3
4
5
Intent to implement mandatory vaccination policy from 1 January 2022
>30k	>220k excess deaths since May 2020
>14k client deaths
20 employee deaths
Lives saved if >60%
population vaccinated
over coming months
50-80% lower risk of infection
70-85% lower risk of hospitalisation
90-95% lower risk of death
Compared to those who are unvaccinated: <1 in 20
Discovery members
showed any signs of
side-effects
50-80% lower transmission risk for
vaccinated individuals
Slow take up in younger cohorts
100% Target vaccination take-up
Clear moral and social obligation as informed by our
Core Purpose to make people healthier and to
enhance and protect their lives
>890k members of Discovery Health administered schemes
vaccinated
300k individuals outside of this
DSY has helped vaccinate:
6

-- 12 of 81 --

13
30-Jun-20 30-Jun-21	30-Jun-20 30-Jun-21
-3000
-2500
-2000
-1500
-1000
-500
0
500
Individual Life Group Life New
individual Life
provisions
net of
margins
AURR Group
Life
FY21 earnings
impact
FY20 earnings
impact
Increasing the COVID-19 provision in SA, and releasing in the UK
Provisions more than sufficient
due to UK’s effective and early
vaccine campaign
Provisions and positive lapse experience in Individual Life more than sufficient to cover in-
period COVID-19 claims, net loss recorded in Group Life
Discovery Life Vitality Life
R2 160m
R2 693m
COVID-19 provisions	Income statement impact
(R2 448m)
In period COVID-19
impact net of provisions
and lapse gains
£28.8m
£5.4m
R2 800m Life provisions across the Group
R2 448m DL earnings impact for period under review
COVID-19 provisions
(R1 058m)
*Claims provision release of R1175m + lapse gain of R831m minus identified COVID-19 claims of R1673m
*

-- 13 of 81 --

Resilient
operating performance
2

-- 14 of 81 --

15
Health 3 423 +7% 6 453 +6%*
Life 1 341 -55% 2 264 -1%
Invest 1 084 +31% 2 737 +3%
Insure 250 +2% 1 287 +18%
Bank (1 094) -7% >81 000
New-to-Bank
clients
+86%
Vitality Health 953 +15% 1 367 +10%
Vitality Life 644 +337% 1 141 -9%
Vitality Group 417 +35% 1 270 +12%
Ping An Health 411 +126% 3 938 +10%
Other New (978) -7% 2 114 +156%
+11%
New business
R22.6bn
+7%
Operating profit
R6.5bn
Continued operational excellence, growth in DHMS lives and providing significant support
to members and society
Significant negative COVID-19 mortality impact but delivering positive actuarial variances
through excellent retention experience and maintaining financial strength
Strong earnings growth, retention and excellent investment returns for customers. New
business growth curtailed by lower guaranteed plan sales
Strong new business growth and robust underwriting performance with earnings impacted
by lower investment yields
Robust operating performance driven by continued good retention. Careful management
of delay of elective healthcare in the COVID-19 environment
Strong recovery, strengthening of underlying actuarial basis and successful execution of
management plan. New business slowed with lockdowns and the focus on quality business
Robust growth due to increasing integration and traction with existing partners and
accelerating roll-out to new markets and adjacencies
Focus on profit quality and scale through both distribution channels and product
diversification. Capital injection to support long-term growth
Strong high-quality client and deposit growth while deliberately pursuing a prudent,
quality-focused credit strategy
Lower spend combined with excellent growth in new business API
*Including new closed schemes
Resilient performance

-- 15 of 81 --

16
-
5,000
10,000
15,000
20,000
25,000
2017 2018 2019 2020 2021
Health Life Invest Vitality
VH VL Emerging New
Operating profit and New business
Operating profit
Before SA COVID-19 impact
-
2,000
4,000
6,000
8,000
10,000
2017 2018 2019 2020 2021
Operating profit COVID-19 impact
+25%
+7%
SA mortality
New business
Including new closed schemes and Vitality Group
Emerging and New growing strongly
38%
11%
-
5,000
10,000
15,000
20,000
25,000
2017 2018 2019 2020 2021
+11%
+5%
+14%
+10%
Recovered from 2020 COVID-19
impact, 8% CAGR on 2019
Emerging
and New
Emerging
and New
Emerging
and New
Established

-- 16 of 81 --

17
Resilient operating performance, actuarial dynamics
within expectation
Lapses	
– vs expected
Claims	
– vs expected
Paid up
Withdrawals
Health Life Invest Insure Health Life
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
 0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
 0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
 0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
 0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
98%
91%
FY AvE
76%
100%1
76%
82%
92%
98%
88%
84%
72%
102%2
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
0%
50%
100%
150%
Jul
Sep
Nov
Jan
Mar
May
1 Individual Life, excluding identified COVID-19 claims
2 Excluding identified COVID-19 claims

-- 17 of 81 --

18
Reported profit for period affected by foreign exchange movements
Rm
12 months
ended
Jun 2021
12 months
ended
Jun 2020
%
Normalised profit from operations 6,494 6,069 7%
Economic assumptions adjustment DL -411 -3,635
Economic assumptions adjustment VL -108 -1,195
Finance charges excl. 1DP finance lease -1,291 -1,218
Unrealised (losses)/gains on foreign exchange contracts not designated as a hedge -304 263
Foreign exchange (losses)/gains -389 578
Deferral fees related to Prudential Book transfer -187 -71
Investment income and fair value remeasurements 83 338
Dilution gains from equity accounted investments 554 3
Other -234 -609
Profit before tax 4,207 523 704%
Tax -987 -347
Profit attributable to preference and minority shareholders -63 -79
Profit attributable to equity holders 3,157 97 3155%
Headline adjusting items -171 199
Headline earnings 2,986 296 909%
Economic assumptions adjustment (DL and VL) 383 3,584
Other normalisation adjustments 37 -133
Normalised headline earnings 3,406 3,747 -9%
Forex exchange (gains)/losses net tax 305 -424
Normalised headline earnings excl forex impact 3,711 3,323 +12%
Due to the continued uncertainty and
potentially volatile economic environment
caused by the COVID-19 pandemic, the
Discovery Board has decided to retain its
prior stated position during the pandemic
and has decided not to declare an ordinary
final dividend for the period ended 30 June
2021. The reintroduction of an ordinary
dividend will be considered on an ongoing
basis
1
2
3
1
2
3
Stabilisation of long term interest
rates in SA and the UK resulted in
materially lower economic basis
changes than the prior year, R4.3bn
swing
Mark-to-market foreign currency
losses arising from a recovery of the
Rand during the reporting year
compared to a gain in the previous
financial year, R1.5bn swing
Unrealised gain from the transaction
in which Cambridge Mobile Telematics
(CMT) acquired TrueMotion

-- 18 of 81 --

Capital strength
and liquidity
3

-- 19 of 81 --

20
Group is well capitalised and highly liquid
Jun 20
Cover
Jun 21
Cover
Life 1.8x 1.8x
Insure 1.8x 1.8x
VH 1.7x 1.6x
VL 2.0x 2.4x
Bank1 1.6x 1.4x
PAH 1.9x 2.3x
1 Capital Adequacy Ratio
2 Considers SA Liquidity and liquid excess assets for Discovery Life, Discovery Insure, VitalityHealth, VitalityLife and Discovery Bank
3 SA cash + undrawn committed facilities
SA Liquidity3 , R millions	FLR R millions
Liquid excess assets above minimum
regulatory capital requirements
Strongly capitalised FLR is within target
Highly liquid across
the Group2
Sufficient liquidity
at the centre
-
5,000
10,000
15,000
FY18 FY19 FY20 FY21
DHMS solvency 36.9%
15%
17%
19%
21%
23%
25%
27%
29%
FY17 FY18 FY19 FY20 FY21
28%
25.7%
-
500
1,000
1,500
2,000
FY18 FY19 FY20 FY21

-- 20 of 81 --

21
Cash
generated
Cash
used
Funding
New business
Net cash flow1
New businesses
Net cash
generated from
in-force business
R13.0bn
Tax and finance
costs
R2.6bn
R7.9bn
R1.3bn
R1.8bn
Cash generation positive prior to COVID-19
R13.0bnCash generated from in-force
1 Movement in shareholder free cash
R14.3bn
Cash used net of funding
(R1.3bn)
Net cash flow
Reinsurers
Debt
R1.0bn
Vitality Life
Vitality Health
Discovery Life
and Invest
Discovery
Health
Gross Life
COVID-19
claims
R3.0bn

-- 21 of 81 --

22
Opening EV Value of new
business
Unwind of risk
discount rate
Non-Economic
Experience
Variances and
Methodology &
Assumption
Changes
COVID-19
impact
Operational EV Economic
Experience
Variances and
Methodology &
Assumption
Changes
Forex Other Closing EV
4.6% Annualised ROEV
11% excluding COVID-19,
forex and economic changes
Group Embedded Value
R74 645m
R78 608m
R70 834m
~25%
total adjusted revenue1
attributable to Emerging and New
Group revenue
1 Including 25% Ping An Health earned premium and Bank NII and NIR and excluding insurance premium revenue from the Invest segments
-
10,000
20,000
30,000
40,000
50,000
60,000
70,000
2017 2018 2019 2020 2021
Total Group
Group excl Emerging and New
Rm

-- 22 of 81 --

Three dimensions
of growth
4

-- 23 of 81 --

24
The rise of digital
Ways of work
Ecommerce
Telemedicine
Contactless
ESG
Moral money
Climate change
Social movements
Mortality
Morbidity
Driving
Investing
Banking
Significant increase in ecosystem strategies globally
Insurtech and ecosystem
strategies are increasing
Many have invested substantially into
health ecosystems2
76%
p.a.
1 CB Insights
2 McKinsey 2021
77x
(of 11/20)
8x
(of 2/20)
16x
(of 4/20)
20x
(of 5/20)
40x
(of 10/20)
Sample of 20 large insurers globally have strategically invested into
various ecosystems over the last few years, with health being a
prominent theme (32% of investments)
Blurring of boundaries
in these three trends
Number of mentions of ecosystems in
leading European insurers and medtech
providers2
xx Health funding in EUR m Core business Funded health start-ups
Funded start-ups from other ecosystems (mobility, housing, education, B2B services)
Record quarter for insurtech
investment activity1
-
500
1,000
1,500
2,000
2,500
3,000
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
2016 2017 2018 2019 2020 2021
USD m

-- 24 of 81 --

25
Evolving the business model to an ecosystem
Institution
Platform
Ecosystem
Bank	Motor	Invest	Life	Health
Institution
 
Platform
Composite
“Make people healthier”

-- 25 of 81 --

26
Three dimensions of growth
1 2 3
Geographic growth Platform-led growth	Organic growth
Expand the Vitality global insurtech
platform
Create superior institutions
Grow globally with the ability to
repeat and scale
Grow organically
Build new businesses that scale
Achieve superior returns on capital
ESTABLISHED
EMERGING
NEW
Institution
 
Platform

-- 26 of 81 --

27
Emerging
businesses
are scaling
rapidly
Organic growth
R1.1bn
R2.0bn
R9.9bn
(-1% to R7.5bn)
ESTABLISHED
EMERGING
NEW
% in New*:
19%	24%	14%	7%	5%
-
5,000
10,000
2017 2018 2019 2020 2021
After COVID-19 impact COVID-19 impact
-500
-
500
1,000
1,500
2017 2018 2019 2020 2021
-3,000
-2,000
-1,000
-
2017 2018 2019 2020 2021
+46%
+74%
+94%
+15%
+0%	+3%	+13%
-1%	-13%
*Pre-COVID-19 impacts
New definition is as % of core (Established and Emerging) instead of total operating profit
Operating profit
23%	31%	17%	8%	5%
New
Old definition
Established
businesses
remain robust
SA mortality
+46%
to
+15%
to
Turning point
in the spend
on New
businesses
1

-- 27 of 81 --

28
Emerging businesses are growing rapidly and achieving good returns
2017 2018 2019 2020 2021
+2%
Insure Vitality Group	Ping An Health
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
ROE ROE ROE
10.4%
-200
-
200
400
600
800
1,000
1,200
2017 2018 2019 2020 2021
Operating profit Operating profit Operating profit
Strong growth from Emerging
Operating profit Rm
14.5%ROE
Normalised RoE in local currency, and only considers Emerging parts of business – Insure excludes CMT and VG excludes new initiatives

-- 28 of 81 --

29
New businesses are seeing considerable traction
Bank Vitality1	Vitality Invest DBI Umbrella Funds
0
200
400
600
800
1,000
1,200
1,400
FY19 FY20 FY21
Millions
0
5
10
15
20
25
30
35
40
FY19 FY20 FY21
+86%New-to-Bank Clients
+75%New business (£m) New markets launched
FY20-FY21
+52%New business
+290%New business
0
20
40
60
80
100
120
140
160
180
200
FY19 FY20 FY21
Millions
-
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
90,000
FY19 FY20 FY21

-- 29 of 81 --

30
Geographic growth
+6% to
R7.1bn
(-17% to R4.7bn)
Operating profit Operating profit
3,000
4,000
5,000
6,000
7,000
8,000
2017 2018 2019 2020 2021
After COVID-19 impact COVID-19 impact
+6%	+1%	-5%
+9%
-17%
-15%
SA mortality
-
500
1,000
1,500
2,000
2017 2018 2019 2020 2021
+334%
-61%	+12%
+84%
2
DBI Umbrella Funds VG New

-- 30 of 81 --

31
Platform-led growth
ENHANCED INSURANCE
VALUE CHAIN
TECHNOLOGY AND ANALYTICS LAYER
DATA LAYER
BEHAVIOURAL LAYER
INCENTIVE LAYER
PRODUCT LAYER
PREDICT VALUE INTERVENE
Attract Price Change Behaviour Retain
BEHAVIOURAL DESIGN
Nudge theory Loss Aversion
GLOBAL INTEGRATED PARTNERS
Resonance design	Pre-commitment
PREDICT INTERVENE
FUTURE HEALTH 
Next-best
action model
Gateway
Portal
GLOBAL DATA ENGINEERING
HEALTH
>50m
Life years of
behavioral linked
insurance data
300k
New members
every month
>3.5m
Device tracking
events a week
13bn
INSURANCE PRICING
Device-
led
Wedge
funding
Dynamic
pricing
BEHAVIOURAL VALUE MATCHING
Net VIF uplift model
PLATFORM ENABLEMENT MOBILE CONTENT MANAGEMENT	VITALITY 1
World-class technology platform Transforms Vitality customization Enables instant multi-language
launches
3
km tracked
ABC
pricing

-- 31 of 81 --

32
Platform seeing good engagement and growth
Customer engagement
12bn Average steps per
day
3.5m Workouts logged
per day
4k New devices
registered per day
20k Health assessments
per day
600k Goals achieved per
week
41m Impacted lives
30 Markets
Platform income* Shared Value outcomes
SA UK Market A
SA UK
Life
Insurance
Health
Insurance
Motor
Insurance
Long-term
Savings
Banking
Actuarial value – initial selection, better retention, improved
claims, lower prices, selective lapses
Arrears
Shared Value to
customers in FY21
2,499	1,864
245
Premium discounts
Cash backs
Boosts
R4.6bn
R4.0bn
+8%
Revenue through the platform
(Rm)
*Platform income made up of Vitality membership premiums and Vitality Group revenue
2019 2020 2021
Offshore SA Blue Bronze Silver Gold and
Diamond
Claims ratios by status

-- 32 of 81 --

33
1
2
4
3
Manifesting as unique composites and partnerships
Perfect composite model, #1 in every industry, and the Bank pivoting to growth as the composite-maker within SA
Best-in-breed products across businesses and operating as a fully integrated composite business with a seamless
One Vitality client journey. A successful entry into motor insurance
Vitality is the world’s largest and most sophisticated behavioural platform linked to financial services
Ping An Health delivers on its plan to become the leading health insurer in China with over 50m clients
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health	
Vitality Health	
Vitality Car	
Vitality Life	
Vitality Invest
Global Network
USA

-- 33 of 81 --

34
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
Strong high-quality client and deposit
growth while deliberately pursuing a
prudent, quality-focused credit strategy

-- 34 of 81 --

35
Discovery Bank
Total accounts Retail deposits	Total clients Advances Spend
307k
362k
J A S O N D J F M A M J
Primary Secondary
505k
649k
J A S O N D J F M A M J
R3.1bn
R8.2bn
J A S O N D J F M A M J
R3.6bn
R3.8bn
0.00
500,000,000.00
1,000,000,000.00
1,500,000,000.00
2,000,000,000.00
2,500,000,000.00
3,000,000,000.00
3,500,000,000.00
4,000,000,000.00
J A S O N D J F M A M J
R1.1bn
R20.2
J A S O N D J F M A M J
362k 649k R8.2bn R3.8bn R20.2bnYTD spend

-- 35 of 81 --

36
A full-service shared-value Bank
Banking
ecosystem
Behavioural
Functionality
1
2
3
4
5
High-quality client growth
Attracting deposits
Growing quality advances
Market-leading functionality
Powerful shared-value
fundamentals and currency
Strategic focus areas

-- 36 of 81 --

37
1. Strong growth to ±500 average daily sales with high-quality growth
Quality client growth Opportunity within DSY and
non-DSY client base
New-to-Bank daily sales
±500 average daily
new-to-Bank sales
Achieved the medium-term targets
60%
40%
Bank client with DSY products Bank only
DSY Bank Big 4 Top 5 Retail
Banks
Primary versus secondary clients
Big 4 and Top 5 NIR is the client-weighted average
Big 4 include Standard Bank, FNB, ABSA and Nedbank
Top 5 Retail Banks include Standard Bank, FNB, ABSA, Nedbank and Capitec
9% 13% 20% 26% 32%
Blue Bronze Silver Gold Diamond
Current penetration Opportunity
Vitality penetration
92%
Primary Secondary
DSY product uptake – Bank new business
198
264
353
490
0
100
200
300
400
500
600
FY21 Q1 FY21 Q2 FY21 Q3 FY21 Q4
Average NIR per client per month

-- 37 of 81 --

38
2. Deposits have continued their strong growth trajectory
Deposits are sticky and diverse	Consistent growth in retail deposits
38%
13%
49%
Duration
> 3 months
< 3 months - None/Blue
< 3 months - Bronze+
5%
95%
Concentration
Top 10 depositors
Others
R3.1bn
R8.2bn
J A S O N D J F M A M J
R8.18bn
Growth of 167% from July 2020 to June 2021 vs 7% for the market

-- 38 of 81 --

39
3. Deliberate decision to pursue a prudent, quality-focused credit
strategy
Superior credit risk
metrics
Credit loss ratio	Retail advances New-to-Bank credit
application metrics (excl. COVID-19 overlay)
3.96%
0%
3%
6%
9%
J A S O N D J F M A M J
R3.6bn
R3.8bn
0.00
500,000,000.00
1,000,000,000.00
1,500,000,000.00
2,000,000,000.00
2,500,000,000.00
3,000,000,000.00
3,500,000,000.00
4,000,000,000.00
J A S O N D J F M A M J
Growth of 5% from July 2020 to June
2021 – above market growth of 4.5%
34% 52%
0%
50%
100%
Discovery Bank Market
Subprime Near prime Prime
Prime plus Super prime
NEW CLIENTS RISK DISTRIBUTION
JAN – MAR 2021
EXISTING CLIENTS RISK DISTRIBUTION
JAN – MAR 2021
17% 30%
0%
20%
40%
60%
80%
100%
Discovery Bank Market
0%
5%
10%
15%
20%
25%
30%
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
FY21
Q1
FY21
Q2
FY21
Q3
FY21
Q4
Applications Approve rate

-- 39 of 81 --

40
202007
202008
202009
202010
202011
202012
202101
202102
202103
202104
202105
202106
4. Shared-value fundamentals emerging as expected with Discovery
Miles as a powerful currency
The Discovery Miles currency is central to the Bank’s ecosystem and
the SA composite
Shared-value fundamentals
94%lower arrears
rate
Gold and Diamond
vs Blue
3.20%
1.26% 0.62%
0.18%
Blue Bronze Silver Gold and
Diamond
1 2 12
92
Blue* Bronze Silver Gold and
Diamond
1 1 2
4
Blue Bronze Silver Gold and
Diamond
Indexed to Blue
9xhigher average
deposits
Gold and Diamond vs
book average
4xgreater spend
Gold and Diamond vs
Blue
Online and in-
store
Prepaid products
and services
Travel
Transfer and
convert
Physical activity
Drive
Spend
Healthy living
Get up to when you spend
Discovery Miles in the Vitality Mall, online and
on prepaid products and services
in FY2021
4.9bnearned
2.9bnspent
in FY2021
Cumulative Miles earned
1
5.5 8.5
Daily average Black Friday Miles D-Day
(July)
Miles spend
Continuous innovation
New ways to
earn Miles
New ways to
spend Miles

-- 40 of 81 --

41
5. Differentiated, market-leading functionality with a focus on digital
sophistication
Continued innovation Continued innovation
Innovations successfully rolled out Several enhancements being rolled out in
September
Account
origination
Payments
Account
management
Rewards
Service
Travel
Security
?
 Sign up 24/7/365 in <5 mins
 Transact immediately with a
Virtual Card
 Apple Pay
 Discovery Pay
 Seamless account setup
 Manage accounts and cards in-App
 Live Assist
 24/7/365 online
 Shared-value stack: Interest rates,
shopping & retail discounts
 Miles more valuable than cash at a
broad partner network
 Discounts on local and international
flights
 Lounges
 FastTrack
“Four-Factor protection”:
 Smart delays: Geo-fencing and AI
account monitoring, hard daily
transfer caps, distressed facial
recognition
Examples; not exhaustive
Forex proposition
Health Pay and
Vitality Pay
Financial
Analyser Smart Vault
1
2
3
Simple account
opening in under
two minutes
Real-time
exchange rates
and transactions
Easily manage
foreign currency
allowances

-- 41 of 81 --

42
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
Continued operational excellence, growth in
DHMS lives and providing significant
support to members and society

-- 42 of 81 --

43
Discovery Health
Membership	Direct manex	Normalised operating
profit
New business
>3.7m
lives under administration
Rm (plpm)
+7%
to R3 423m
+3%
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
1993	
1995	
1997	
1999	
2001	
2003	
2005	
2007	
2009	
2011	
2013	
2015	
2017	
2019	
2021
Non-scheme products
Closed schemes
DHMS
127.93 133.48
2020 2021
+6%to R6 453m

-- 43 of 81 --

44
Discovery Health Medical Scheme performance summary
Value Security	Growth and stability
R2.2bn
Contribution savings for DHMS
members
Delayed contribution increase
DHMS
Scheme A	
Scheme B	
Scheme C	
Scheme D	
Scheme E	
Scheme F
2021 weighted average increases
2.95%
36.9% Solvency1
AAA GCR credit rating1
>2.75m
57% market share2
lives1
5.2% lapse rate1
Debit order rejections
4%
5%
6%
7%
Source: Discovery Health Medical Scheme and the Council of Medical Schemes
1 As at 31 December 2020
2 Based on beneficiaries, according to the Council for Medical Schemes Quarterly Report for the period ended 30 September 2020
2002 2004 2006 2008 2010 2012 2014 2016 2018 2020
R27.5bn reserves1
Reserve build-up

-- 44 of 81 --

45
0
100
200
300
400
500
600
-
0.4
0.8
1.2
1.6
2.0
Mar - 20 May - 20 Jul - 20 Sep - 20 Nov - 20 Jan - 21 Mar - 21 May - 21 Jul - 21
OH Claims GP Consults OTC Meds
Pre-COVID levels
Utilisation patterns, which are the main driver of medical inflation,
have been disrupted
Wave 1 peak
Wave 2 and 3 peaks	COVID-19 admissions
IN-HOSPITAL
CARE
OUT-OF-
HOSPITAL CARE
COVID-19
ADMISSIONS 1
2
3
-
1,000
2,000
3,000	Pre-COVID levels
Total hospital admissions

-- 45 of 81 --

46
Emerging non-COVID-19 utilisation patterns over the period
2 3
IN-HOSPITAL CARE OUT-OF-HOSPITAL CARE
Reduced across the board, with a shift from large
acute hospitals to smaller day surgery type facilities
Starting to increase, with increased care at home
and changes in health-seeking behaviour
Decline in preventative
and screening care
Move to care outside
large hospitals
Decline in discretionary
medical admissions
Decline in maternity-
related utilisation
Spike in pathology
claims
Depression registrations
-20%
Diabetes management
-27%
Breast cancer screening
-55%
Cardiac
catheterisation
Endoscopies
Tonsillectomy
and adenoid
Admissions
Admissions
Claimants
Admissions
Spinal medical
procedures
Proportion of admissions
occurring in a day clinic
2016 2017 2018 2019 2020
+56%
0
100,000,000
200,000,000
300,000,000
400,000,000
500,000,000
600,000,000
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
2019 2020 2021
% Pre-38 week
births
Admissions
average LOS
Neonatal
admissions
NICU
admissions

-- 46 of 81 --

47
Accelerated digitisation of the healthcare system | DH ideally positioned
Discovery Health has a fully integrated digital healthcare platform	Global expansion of
digital healthcare
% of US consumers using telehealth
Growth in provider
remote consults 2019 to
2020
~ 50 – 175 x
11%
46%
2019 2020
Evidenced by telemedicine use Platform achieved scale
through vaccination journey
129,640
269,907
1,118,689
2019:
DrConnect
(Pre-COVID)
2020:
DrConnect
(COVID)
2021:
Connected
Care (Since
1 Apr-21)
Member logins
Ecosystem has a comprehensive patient record, and
connects the communities of doctors, members and
case managers across a common platform with
integration to various parts of the medical system
DH is already deploying AI and
digitisation for homecare and
enhanced quality
1.01m
logins
Connected Care Vaccine Navigator
3.68m
logins
Detailed medical
examinations and
advanced virtual
consultations
24/7 doctor support
End-to-end digital
experience
Convergence of clinical and data insights
to offer high quality care at home

-- 47 of 81 --

48
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
Significant negative COVID-19 mortality impact but delivering
excellent retention experience and maintaining financial strength

-- 48 of 81 --

49
Discovery Life
Strong capital and liquidity position	New business API	Normalised operating profit
2017 2018 2019 2020 2021
COVID-19 impact
-55%to R1 341m
-6% Before
COVID-19 impact
-1%to R2 264m
2017 2018 2019 2020 2021
182% 183%
2020 2021
4,149
4,420
2020 2021
125%
SCR target
FY21
net cash
outflow
7x
SCR coverage Liquidity coverage

-- 49 of 81 --

50
Discovery Life gross COVID-19 claims
Total (Rm)
-
100
200
300
400
500
600
700
800
Mar-20
Apr-20
May-20
Jun-20
Jul-20
Aug-20
Sep-20
Oct-20
Nov-20
Dec-20
Jan-21
Feb-21
Mar-21
Apr-21
May-21
Jun-21
Jul-21
Aug-21
Sep-21
Oct-21
Nov-21
Dec-21
Jan-22
Feb-22
Mar-22
Apr-22
May-22
Jun-22
Actual Provision Scenario
FY 2021 FY 2022*
Wave 1 = R538m
Wave 2 = R1 871m
Wave 3
to 30 June 2021 = R689m
FY 2020
Provision Scenario
 Prudent best estimate
 60% vaccination by November
Monthly Death Outgo (R’m)
Individual (Rm) 31
Group (Rm) 24
Total (Rm) 55
Individual (Rm) 2 207
Group (Rm) 835
Total (Rm) 3 042
Individual (Rm) 2 253
Group (Rm) 866
Total (Rm) 3 119
Actual to Aug 21 (Rm) 2 156
4 491
1 725
6 216

-- 50 of 81 --

51
Premiums
and fees
Claims Reinsurance Existing
financing
cashflows
Operational
costs
Cashflows
from
existing
NB strain Net Life and
Invest
cashflow
after FinRe
Robust embedded value growth driven by positive operating variances
with continued exceptional persistency experience
Maintained strong positive
operating variances
2020 2021
Embedded Value
+10%
401
2010	
2011	
2012	
2013	
2014	
2015	
2016	
2017	
2018	
2019	
2020	
2021
Non-economic EV Variances
(Rm)
421 411
2020 2021
5.8% 5.7%
2020 2021
VNB VNB Margin
31.8bn 34.8bn
Excluding COVID-19
7.1%
8.0%
519
586
VNB impacted by lower
volumes and COVID-19
provision strengthening
Cashflow impacted by COVID-19 claims
Rm
Gross COVID-19 claims R3bn
Overall COVID-19 impact on cashflow of cR1.5bn net of
all risk and financial reinsurance
-633
2 196
15 694

-- 51 of 81 --

52
Looking ahead and optimising Life insurance post the 3rd wave
1 Well capitalised
and highly liquid
2
Highly engaged
and vaccinated
client base
3 Products adjusted
for COVID-19
Supported strong
back book cash
generation: >R15bn
premium income
182% 183%
2020 2021
4,149 4,420
2020 2021
125%
SCR target
FY21
net cash
outflow
7x
SCR coverage Liquidity coverage Back book cash generation
Actively driving vaccinations
Differentiate between
vaccinated/unvaccinated lives
Product features
VACCINATION MAX
OFFER
Understanding relative COVID-19
risk across age bands
20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95
Base mortality
rate at age 45
None Blue Bronze Silver Gold Diamond
off
Bronze	38%
High Vitality engagement
% Life book vaccinated to
date Count basis Sum assured basis
% of total book 57% 62%
% of 60+ years 73% 77%
% of 50+ years 69% 71%
% of 35+ years 63% 66%

-- 52 of 81 --

53
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
Strong earnings growth, retention and excellent investment returns
for customers. New business growth curtailed by lower guaranteed
plan sales

-- 53 of 81 --

54
New business
+3%
Rm
Assets under
administration
+18%
Rbn
2017 2018 2019 2020 2021	2017 2018 2019 2020 2021
+16%
+31%
2019 2020 2021
Discovery Invest
to R2 737m
2017 2018 2019 2020 2021
to R117bn
Non-recurring profit contributions,
include release of COVID lapse
provisions and GILF matching profits
Normalised operating
profit
+31%
Rm
Lapse rates
-13%
to R1 084m

-- 54 of 81 --

55
Key highlights over the past financial year
12% increase in linked product
sales
More profitable business sold over the last
financial year, with offshore sales up 81%
Linked products as proportion of
new business
57% 68%
2020 2021
Strong investment performance Shared value continues
to drive good outcomes
+3 years
Average
investment term
+338%
In extra
contributions
-22%
Income withdrawal
level
One year Three year Five years
Discovery Dynamic Asset Optimisers
Conservative Q1 Q1 Q1
Moderate Q2 Q1 Q1
Aggressive Q1 Q1 Q1
Discovery Balanced Funds
Balanced Q2 Q2 Q2
Moderate Balanced Q2 Q2 Q1
Cautious Balanced Q2 Q1 Q1
Multi-asset
26% Flexible Property
22%
Local single-asset*
Equity
Global equity*
34%
16% Equity Feeder
Value
*Growth over one year

-- 55 of 81 --

56
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
Strong top-line growth and robust underwriting performance with
earnings impacted by lower investment yields

-- 56 of 81 --

57
Discovery Insure
Personal Lines only. Assumes 6% in GWP
market growth since 2018	*Personal Lines only
Normalised
operating profit
+2%
New business
+18%
Gross written
premium
+15%
Market share
in GWP
7%
Operating
margin*
6%
to R250m
(excl. Commercial)
to R4 205*	to R1 287m*
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021	2017 2018 2019 2020 2021	2017 2018 2019 2020 2021

-- 57 of 81 --

58
Analysing the profit dynamics
CMT profits are net of SA costs
COVID-19 had an impact on driving,
claims and profit in FY21
2020 2021
0
50
100
J F M A M J J A S O N D J F M A M J J
Infections (k)
100%
19%
60%
0%
40%
80%
120%
J F M A M J J A S O N D J F M A M J J
Driving activity
2020 2021
Infections
Driving Activity v regular levels
R56m
additional
actual profit
R114m
additional
profit
R58m
additional
rewards given
- =
(R59m in FY20)
Normalised
Operating
Profit
CMT Investment
Income
Operating
Profit
Profit composition reveals a strong increase in core
operating profit (Rm)
FY20	FY21
Normalised
Operating
Profit
CMT Investment
Income
Operating
Profit
246
-13
-114
119
Covid
related
250
-3
-84
163
Covid
related

-- 58 of 81 --

59
The Vitality Drive model improves each year
28%
proportion of book shifted over
4 years to Silver and up
2017 2018 2019 2020 2021
Blue Bronze Silver Gold
Gold	
Blue
Bronze
Silver
Status correlations well established
Gold	
Blue
Bronze
Silver
Loss ratio by status Lapse ratio by status
Improved status distribution
leverages these dynamics
-34%
This manifests iteratively in
an improving claims ratio
-65% 60%
56% 55%
51% 52%
2017 2018 2019 2020 2021
Motor claims ratio Total claims ratio
56% 55%
52%
44%
47%
2017 2018 2019 2020 2021

-- 59 of 81 --

60
Vitality Health	
Vitality Car	
Vitality Life	
Vitality Invest

-- 60 of 81 --

61
UK Composite
GBP millions	
GBP millions	
GBP millions
Vitality Health, Vitality Life, Vitality Invest and Other
1 Vitality Health and Vitality Life only
Earned
premiums1
+5%
Lives covered
+8%
to £827.4m to 1.4m lives
Normalised
operating profit
+844%
New business
+7%
to £68.5m to £156.7m
Vitality Health	
Vitality Car	
Vitality Life	
Vitality Invest
Best-in-breed products across
businesses and operating as a fully
integrated composite business with a
seamless One Vitality client journey. A
successful entry into motor insurance

-- 61 of 81 --

62
Robust operating performance driven by continued good
retention. Careful management of delay of elective healthcare
in the COVID-19 environment
Vitality Health	
Vitality Car	
Vitality Life	
Vitality Invest

-- 62 of 81 --

63
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021	2017 2018 2019 2020 2021
Vitality Health
GBP millions	
GBP millions	
GBP millions
Earned premiums
+4%to £515.6m
Normalised
operating profit
+9%
New business
+5%to £46.0m to £65.9m
2017 2018 2019 2020 2021
Lives covered
+6%to 723k lives

-- 63 of 81 --

64
Operational performance continues to be outstanding and business
well prepared for the coming period
Stronger and
better retention
Low loss ratios, but
returning to prior levels
100
68
58 59 54
2017 2018 2019 2020 2021
Lapse Rate Actual v Pre-COVID expected loss
ratio has precipitated a surplus
98
106
76
3233
43
67
74
88848783
72
8482
93
99
105
Jan Mar May Jul Sep Nov Jan Mar May
2020 2021
FY21
Pre-COVID expectation = 100
36.1
14.2
39.7
2020 2021
Rescheduled FinRe
UPR
Short-term
increase in claims
within contract
boundary
Providing for longer-
term increases:
1. Long Covid
2. Long term
increase in
claims e.g.
cancer increases
3. Catch-up
experience-
based premium
increases
Good cash generation
Cash
generated
from
inforce
Write new
business
Invest in
project
initiatives
Net cash
generated
£128m
£56m
Provided for uncertain future
claims through UPR and
rescheduled FinRe
£m

-- 64 of 81 --

65
Strong recovery, strengthening of underlying actuarial basis and
successful execution of management plan. New business slowed with
lockdowns and the focus on quality business
Vitality Health	
Vitality Car	
Vitality Life	
Vitality Invest

-- 65 of 81 --

66
Vitality Life
Earned premiums
+8%
Lives covered
+10%
to £311.8m
Normalised
operating profit
+325%
New business
-14%
to £31.0m to 680k lives to £55.0m
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021	2017 2018 2019 2020 2021	2017 2018 2019 2020 2021
GBP millions	
GBP millions	
GBP millions

-- 66 of 81 --

67
Expected
operating profit
Experience
variances (excl.
COVID-19)
COVID-19
claims and
lapse variances
COVID-19
provision
strengthening
Basis and
model
strengthening
variances
Normalised
operating profit
£30m
£11.9m £2m £25.8m
£31m
£16.9m
Favourable lapse and COVID-19 experience drove strong profit, but
offset by new business shortfall and assumption changes
Operating profit recon	Addressed the 10 point plan

-- 67 of 81 --

68

-- 68 of 81 --

69
Focus on profit quality and scale through both
distribution channels and product diversification.
Capital injection to support long-term growth

-- 69 of 81 --

70
Ping An Health
1 100% of PAH
Written premium1 PAH’s operating
results pre-tax
to R40.6bn
New business1 Discovery’s operating
result after tax
to R15.8bn to R2.9bn
(DSY’s share is R727m)
to R411m
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021

-- 70 of 81 --

71
The quality of the book and profits have improved
Revenue growth surged in H2 20,
growth moderating in FY21
Written premiums RMB
Focused on quality, as seen by
highest margins in industry
Net margin post tax, Jan - Dec 20
Renewal rates continue to
increase and COR is reducing
Renewal rates
-
2
4
6
8
10
12
H1
FY17
H2
FY17
H1
FY18
H2
FY18
H1
FY19
H2
FY19
H1
FY20
H2
FY20
H1
FY21
H2
FY21
Billions
+58%
+20%
Prior period YTD 2021
7%
absolute
reduction
Source: publicly available financial statements
Company Margin
PING AN HEALTH INSURANCE
COMPANY OF CHINA, LTD 5.40%
KUNLUN HEALTH INSURANCE CO LTD 2.70%
CPIC HEALTH 2.30%
PICC HEALTH INSURANCE COMPANY
LIMITED 0.10%
FOSUN UNITED HEALTH INSURANCE
COMPANY LTD -3.40%
RUIHUA HEALTH ASSURANCE
CORPORATION -28.90%
Combined operating ratio
31-Dec-19 30-Jun-20 31-Dec-20 30-Jun-21
Target

-- 71 of 81 --

72
Continue to pursue scale through diversified distribution channels
and products
Increasing digital presence to unlock the online market
Ping An
Good Doctor App
Le Jian Kang WeChat
mini-program
Home
page Insurance Shop Health
Q&A
My
profile
Urology Paediatrics Dermatology Internal	
medicine TCM
Diabetes Fertility Urinary Male	
health
Medical	
services Cumulative	
services
Earn gold	
status
Quick	
Inquiry TCM	
Specialist Expert	
Doctor Medication Cloud	
farm
Video	
Consult Medical	
examinationInsurance
Health check-up
Access to
*400m users
*As at June 2021
Integrated
products
Integrated
services
New business split by channel
0%
20%
40%
60%
80%
100%
Jun-20 Jun-21
Ping An Life Broker and direct sales
Cross Sales with PAG SuiShenYi online agency
Online and Ping An App
24% 37%

-- 72 of 81 --

73
China’s market and strong economic growth trajectory provide an
excellent long-term opportunity
Policies emphasise developing
healthcare and private health insurance
supported by mature regulations
Continued growth in
healthcare expenditure,
increased participation from
private health insurance
(RMB Trillion)
~USD
2.4trn
6
16
2019 2030
Public sector subsidised
healthcare providers
2019
Private sector
healthcare providers
2030
2.7x
14th five-year plan provides support in four
main areas (2020-2025):
Social development: Promote development of
private health insurance
Digitisation: Develop AI healthcare capability,
online hospitals & digitise health
International Collaboration: Attract foreign
investment and technology in medicine,
telecom, internet and education
Healthy China 2030 target: Increase the
number of people exercising
CBIRC formed in 2018 to combine and strengthen
financial supervision of insurance and banking sectors
CBIRC - China Banking and Insurance Regulatory Commission
Recent regulatory developments in
education, technology and online
pharmacy sectors, to align with policy
goals
Education & housing
regulation address low
birth rate
Technology sector
regulation change
address anti-competitive
practices, consumer
protection and prudent
capital requirements
Online pharmacy
regulations
address online prescription
drug safety

-- 73 of 81 --

74
PAH requires additional capital to support business growth and
product diversification
Total capital injection for PAH to develop additional capabilities and
fund new business growth
Capital requirement driven by 2 factors
PAH growth imperatives
along with 200%
solvency requirement
Change in solvency
rules
70%
30%
Cumulative new business portion of
20 year product
Sep-20	
Oct-20	
Nov-20	
Dec-20	
Jan-21
Feb-21	
Mar-21	
Apr-21	
May-21	
Jun-21
32%
PAH’s projected solvency ratio reduces without a capital
injection, due to sales of more capital-intensive 20-year
product
• Strong market demand for renewal guarantee
• Premium increase flexibility for PAH
• More sustainable and profitable product
• Lower average commission over term
• More capital-intensive
• Higher upfront commission
Chinese C-ROSS Phase II regulations implemented in 2021 aim to strengthen the effectiveness of
insurance regulatory system
New requirements increase minimum capital requirements for insurance, market, credit and other
quantitative risk factors

-- 74 of 81 --

75
USA
Strong growth due to increasing integration and
traction with existing partners and accelerating roll-
out to new markets and adjacencies

-- 75 of 81 --

76
Vitality Group
All numbers exclude new VG initiatives, i.e. myOwn and Vitality
1 Excludes services related to system implementation and other cost recoveries and rewards
Revenue1 Operating result
to $82.4m
R1.3bn
Integrated API by
insurance partners
Insurance and franchise
partners membership
to $1.3bn
R19.9bn
to $27.1m
R417m
to 2.4m
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Insurance partners Vitality USA
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
+27%

-- 76 of 81 --

77
-35%*
-35%
Engagement Lapses Claims Up-sales Latent value
Market A
Market B
Market C
Market D
Attachment rates	% of members earned a point
Deepened adoption of SVI model has been transformational for our
partners
74%
58%
72%
54%
40%
45%
75%
80%
Bronze Silver Gold & Platinum	Non-Vitality
-60%
-79%
-18%
+73%
+40%
-10%*	-40% +111%
+98%	
-18%*
*Pricing assumption in lieu of credible experience

-- 77 of 81 --

78
Broadening reach and scale through a repeatable framework
Fully remote implementation period to launch
2-version launch with increased functionality
Accelerated roll-out despite COVID Enabled by unified repeatability strategy
lives
2017 2018 2019 2020 2021

-- 78 of 81 --

79
Shared value health
insurance approach
TECHNOLOGY LAYER
DATA LAYER
BEHAVIOURAL LAYER
INCENTIVE LAYER
PRICING LAYER
Comprehensive Digital
Health Ecosystem
The platform allows an expansion from 1 ecosystem to 3

-- 79 of 81 --

80
Forward-looking focus areas
Capital strength and liquidity remain a focus
Injecting capital into Ping An Health to support
business growth and product diversification
Implement employee vaccine mandate, structural
and pricing changes to products for our customers
and play a central role in state-led COVID-19
response
Create unique shared-value composites that offer
superior value
1 Navigating COVID-19
2 Capital strength and
liquidity
3 Actively pursue the
three dimensions of
growth
4 Execute on the four
strategic strands
Grow businesses organically, scale businesses
offshore and expand the Vitality global insurtech
platform

-- 80 of 81 --

Discovery Limited
Copyright 2021 Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group. Registration number: 1999/007789/06.
Companies in the Group are licensed insurers and authorised financial services providers.

-- 81 of 81 --